Evidence map›Paper›PMID 38937432›Full record

ArticleSignal transduction and targeted therapy2024

A Cullin 5-based complex serves as an essential modulator of ORF9b stability in SARS-CoV-2 replication.

Yuzheng Zhou, Zongpeng Chen, Sijie Liu, Sixu Liu, Yujie Liao, Ashuai Du, Zijun Dong, Yongxing Zhang, Xuan Chen, Siyi Tao and 15 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. NSP7 Molecular Degrader Attenuates Coronaviral Infection Through the β-TrCP1/FBXO5 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yuzheng Zhou *Department of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Zongpeng Chen *Department of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Sijie LiuDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Sixu LiuDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Yujie LiaoDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Ashuai DuDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Zijun DongDepartment of Basic Medicine, School of Medicine, Hunan Normal University, 410081, Changsha, China.
Yongxing ZhangDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Xuan ChenDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Siyi TaoDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Xin WuDepartment of spine surgery, The Third Xiangya Hospital, Central South University, 410013, Changsha, China.
Aroona RazzaqDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Gang XuSchool of Basic Medical Sciences, Anhui Medical University, 230032, Hefei, China.
De-An TanHunan Key Laboratory of Neurorestoratology, 921 Hospital of Joint Logistics Support Force People's Liberation Army of China (The Second Affiliated Hospital of Hunan Normal University), 410003, Changsha, Hunan, China.
Shanni LiDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China.
Youwen DengDepartment of spine surgery, The Third Xiangya Hospital, Central South University, 410013, Changsha, China.
Jian PengDepartment of Geriatric Surgery, Xiangya Hospital, Central South University, 410008, Changsha, China.
Shuyan DaiXiangya School of Pharmaceutical Sciences, Central South University, 410013, Changsha, China.
Xu DengXiangya School of Pharmaceutical Sciences, Central South University, 410013, Changsha, China.
Xianwen ZhangInstitute of Infectious Diseases, Shenzhen Bay Laboratory, 518132, Shenzhen, China.
Taijiao JiangGuangzhou Laboratory, 510005, Guangzhou, China.
Zheng ZhangInstitute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, 518112, Shenzhen, China.ORCID 0000-0002-3544-1389
Gong ChengInstitute of Infectious Diseases, Shenzhen Bay Laboratory, 518132, Shenzhen, China.ORCID 0000-0001-7447-5488
Jincun ZhaoInstitute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, 518112, Shenzhen, China.ORCID 0000-0003-2515-5589
Zanxian XiaDepartment of Cell Biology, School of Life Sciences, Central South University, 410013, Changsha, China. xiazanxian@sklmg.edu.cn.ORCID 0000-0002-5810-1678

Funding

China Postdoctoral Science Foundation 2023M731520National Natural Science Foundation of China (National Science Foundation of China) U21A20384
6 · The paper itself

Abstract

The ORF9b protein, derived from the nucleocapsid's open-reading frame in both SARS-CoV and SARS-CoV-2, serves as an accessory protein crucial for viral immune evasion by inhibiting the innate immune response. Despite its significance, the precise regulatory mechanisms underlying its function remain elusive. In the present study, we unveil that the ORF9b protein of SARS-CoV-2, including emerging mutant strains like Delta and Omicron, can undergo ubiquitination at the K67 site and subsequent degradation via the proteasome pathway, despite certain mutations present among these strains. Moreover, our investigation further uncovers the pivotal role of the translocase of the outer mitochondrial membrane 70 (TOM70) as a substrate receptor, bridging ORF9b with heat shock protein 90 alpha (HSP90α) and Cullin 5 (CUL5) to form a complex. Within this complex, CUL5 triggers the ubiquitination and degradation of ORF9b, acting as a host antiviral factor, while HSP90α functions to stabilize it. Notably, treatment with HSP90 inhibitors such as GA or 17-AAG accelerates the degradation of ORF9b, leading to a pronounced inhibition of SARS-CoV-2 replication. Single-cell sequencing data revealed an up-regulation of HSP90α in lung epithelial cells from COVID-19 patients, suggesting a potential mechanism by which SARS-CoV-2 may exploit HSP90α to evade the host immunity. Our study identifies the CUL5-TOM70-HSP90α complex as a critical regulator of ORF9b protein stability, shedding light on the intricate host-virus immune response dynamics and offering promising avenues for drug development against SARS-CoV-2 in clinical settings.

Indexed as

COVID-19Cullin ProteinsHSP90 Heat-Shock ProteinsSARS-CoV-2UbiquitinationVirus ReplicationBenzoquinonesHEK293 CellsHumansLactams, MacrocyclicProtein StabilityVero CellsViral ProteinsBenzoquinonesCUL5 protein, humanCullin ProteinsHSP90 Heat-Shock ProteinsLactams, MacrocyclictanespimycinViral Proteins

Identifiers

PMID38937432
PMCPMC11211426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.